MedicineMolecular BiologyOncologyGene ExpressionMolecular OncologyTumor ProgressionCancer Cell SignalingCancer GenomicsNoncoding Rna In CancerOncogenic Signaling PathwaysSignal Transduction In CancerTumor Suppressor GenesCabergoline TreatmentCell Growth RegulationMtor Complex 1 RegulationMtor InhibitionMtor SignalingPituitary Tumor Molecular BiologyPituitary TumorigenesisTumor Suppression By Noncoding Rna
Aberrant expression of long noncoding RNA H19 has been associated with tumour progression, but the underlying molecular tumourigenesis mechanisms remain largely unknown. Here, we report that H19 expression is frequently downregulated in human primary pituitary adenomas and is negatively correlated with tumour progression. Consistently, upregulation of H19 expression inhibits pituitary tumour cell proliferation in vitro and tumour growth in vivo. Importantly, we uncover a function of H19, which controls cell/tumour growth through inhibiting function of mTORC1 but not mTORC2. Mechanistically, we show that H19 could block mTORC1-mediated 4E-BP1 phosphorylation without affecting S6K1 activation. At the molecular level, H19 interacted with 4E-BP1 at the TOS motif and competitively inhibited 4E-BP1 binding to Raptor. Finally, we demonstrate that H19 is more effective than cabergoline treatment in the suppression of pituitary tumours. Together, our study uncovered the role of H19-mTOR-4E-BP1 axis in pituitary tumour growth regulation that may be a potential therapeutic target for human pituitary tumours.
54
Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex
Dos D. Sarbassov, David A. Guertin, Siraj M. Ali et al. · Science · 2005 · 6.2K citations
A Chromatin Landmark and Transcription Initiation at Most Promoters in Human Cells
Matthew G. Guenther, Stuart S. Levine, Laurie A. Boyer et al. · Cell · 2007 · 2K citations · Full text
Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Kenta Hara, Yoshiko Maruki, K. Yoshino et al. · Cell · 2002 · 1.8K citations · Full text